Stem cell treatment for multiple system atrophy
Part of Brain & nervous system clinical trials.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 85 years old.
- You need a diagnosis of MSA (either 'clinically established' or 'clinically probable').
- You must have at least one brain MRI sign that suggests MSA.
- You need to have both autonomic failure (like blood pressure or bladder problems) and either parkinsonism that doesn't respond well to standard Parkinson's drugs, or cerebellar ataxia (coordination problems).
- If you can become pregnant, you must not be pregnant and must use an effective birth control method during the trial and for 6 months after the last dose. Male participants with partners who can become pregnant must also use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
This trial provides access to an experimental stem cell treatment made from a patient's own fat cells (adipose-derived mesenchymal stem cells) for people with brain injury. The goal is to see if this treatment can help improve recovery from brain injury.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.